



Pfizer-BioNTech COVID-19 Vaccine Development Program

COVID-19 Vaccine Workshop
January 7, 2021



Two 30 µg Doses of BNT162b2 Induce Neutralizing Antibody Titers Comparable or Higher than Natural Infection



First COVID-19 Occurrence From 7 Days After Dose 2

Phase 2/3 Efficacy – Final Analysis


Subjects WITHOUT Evidence of Infection Prior to 7 days after Dose 2

Efficacy Endpoint	BNT162b2 (30 µg) N=18,198		Placebo N=18,325		VE (%)	(95% CI)	Pr (VE >30%)
	n	Surveillance Time (n)	n	Surveillance Time (n)			
First COVID-19 occurrence >7 days after Dose 2	8	2.214 (17,411)	162	2.222 (17,511)	95.0	(90.3, 97.6)	>0.9999

Total surveillance time: 1000 person-years for all subjects within each group at risk for the endpoint..

Pr=Posterior probability

Cumulative Incidence of COVID-19 After Dose 1



Cumulative Incidence of COVID-19 After Dose 1

